Anavex Life Sciences Corp (AVXL)

[frrol]

Donepezil is an S1 agonist with a higher binding affinity than 2-73 and apparently stronger effects according to some biomarkers as proposed in a recent paper (cited by our company itself). Setting no evidence by lack of DD is not a substitute for no evidence itself, let alone no affirmative evidence. Such a difference is crucial in science research, don't you think.

What would be great is an explanation of this. I'm not expecting this from you, but from the company. Of course, if our human trials show robust efficacy, it is less important. Efficacy is primary for the FDA.